Meeting
2014 ASCO Annual Meeting
Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).
Authors
Ace Joseph Hatch
Duke University Medical Center, Durham, NC
Ace Joseph Hatch , Herbert Pang , Mark D. Starr , John C. Brady , Jingquan Jia , Chen Jiang , Alexander Sibley , Kouros Owzar , Donna Niedzwiecki , Alan P. Venook , Stephanie M. Cushman , Herbert Hurwitz , Andrew B. Nixon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Tumor Biology
Track
Tumor Biology
Sub Track
Proteomic and Metabolomic Biomarkers
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 11022)
DOI
10.1200/jco.2014.32.15_suppl.11022
Abstract #
11022
Poster Bd #
11
Abstract Disclosures
Similar Posters
Poster
2014 Gastrointestinal Cancers Symposium
Prognostic and predictive blood-based biomarkers of overall survival (OS) in patients (pts) with advanced colorectal cancer (CRC) treated with cetuximab (C): Results from CALGB 80203 (Alliance).
First Author: Ace J. Hatch
Poster
2019 Gastrointestinal Cancers Symposium
On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance).
First Author: Ace Joseph Hatch
Poster
2012 Markers in Cancer
Use of epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab (cet) in combination with oxaliplatin (Ox) and 5FU in the first-line treatment of advanced colorectal cancer (aCRC).
First Author: Richard Adams
Poster
2012 ASCO Annual Meeting
Mutant (MT) KRAS codon 12 and 13 alleles in patients (pts) with metastatic colorectal cancer (mCRC): Assessment as prognostic and predictive biomarkers of response to panitumumab (pmab).
First Author: Marc Peeters